Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies.
Pietro Emiliano DonedduChiara BrianiDario CocitoFiore ManganelliGian Maria FabriziSabrina MatàAnna MazzeoRaffaella FazioLuana BenedettiMarco LuigettiMaurizio InghilleriElisa RuiuGabriele SicilianoGiuseppe CosentinoGirolama Alessandra MarfiaMarinella CarpoMassimiliano MirabellaGiovanni AntoniniFrancesca NotturnoStefano SotgiuLaura CucurachiClaudia Dell'AquilaElisa BianchiTiziana RossoAndrea GiordanoMarco FernandesMarta CampagnoloErdita PeciEmanuele SpinaMatteo TagliapietraMartina SpertiLuca GentileCamilla StranoFrancesco GermanoViviana NocitiFederica MoretIgnazio Roberto ZarboDivina Valeria ViolaElisa VegezziGiorgia MataluniStefano Cotti PiccinelliLuca LeonardiAlessandra CartaEduardo Nobile-Orazionull nullPublished in: European journal of neurology (2023)
SARS-CoV-2 vaccination in CIDP and MMN patients does not seem to be associated with an increased risk of relapse at primary endpoint, although a slightly increased risk in CIDP patients was found compared to the 3 months before vaccination.